Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.



This is a "connection" page, showing publications co-authored by Ty Kiser and Paul Reynolds.

Connection Strength
  1. Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014 Jun; 34(6):617-32.
    View in: PubMed
    Score: 0.561
  2. Farrar JE, Mueller SW, Stevens V, Kiser TH, Taleb S, Reynolds PM. Correlation of antimicrobial fraction unbound and sieving coefficient in critically ill patients on continuous renal replacement therapy: a systematic review. J Antimicrob Chemother. 2022 02 02; 77(2):310-319.
    View in: PubMed
    Score: 0.245
  3. Stevens VM, Mueller SW, Reynolds PM, MacLaren R, Kiser TH. Extrapolating Antifungal Animal Data to Humans - Is it reliable? Curr Fungal Infect Rep. 2020 Mar; 14(1):50-62.
    View in: PubMed
    Score: 0.213
  4. Kiser TH, Reynolds PM, Moss M, Burnham EL, Ho PM, Vandivier RW. Impact of Macrolide Antibiotics on Hospital Readmissions and Other Clinically Important Outcomes in Critically Ill Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study. Pharmacotherapy. 2019 03; 39(3):242-252.
    View in: PubMed
    Score: 0.200
  5. Reynolds PM, Van Matre ET, Wright GC, McQueen RB, Burnham EL, Ho PJM, Moss M, Vandivier RW, Kiser TH. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient. Pharmacotherapy. 2019 03; 39(3):232-241.
    View in: PubMed
    Score: 0.199
  6. Stevens VM, Trujillo T, Mueller SW, MacLaren R, Reynolds PM, Kiser TH. Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center. Clin Appl Thromb Hemost. 2019 Jan-Dec; 25:1076029619896619.
    View in: PubMed
    Score: 0.198
  7. Van Matre ET, Reynolds PM, MacLaren R, Mueller SW, Wright GC, Moss M, Burnham EL, Ho PM, Vandivier RW, Kiser TH. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost. 2018 12; 16(12):2492-2500.
    View in: PubMed
    Score: 0.196
  8. Laub M, Fraser R, Kurche J, Lara A, Kiser TH, Reynolds PM. Use of a Cholestyramine Washout in a Patient With Septic Shock on Leflunomide Therapy: A Case Report and Review of the Literature. J Intensive Care Med. 2016 Jul; 31(6):412-4.
    View in: PubMed
    Score: 0.158
  9. Sacha GL, Kiser TH, Wright GC, Vandivier RW, Moss M, Burnham EL, Ho PM, Reynolds PM, Bauer SR. Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock. Crit Care Med. 2022 04 01; 50(4):644-654.
    View in: PubMed
    Score: 0.062
  10. Mueller SW, Kedzior SK, Miller MA, Reynolds PM, Kiser TH, Krsak M, Molina KC. An overview of current and emerging antifungal pharmacotherapy for invasive fungal infections. Expert Opin Pharmacother. 2021 Jul; 22(10):1355-1371.
    View in: PubMed
    Score: 0.058
  11. Stevens VM, Trujillo TC, Kiser TH, MacLaren R, Reynolds PM, Mueller SW. Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding. Clin Appl Thromb Hemost. 2021 Jan-Dec; 27:10760296211039020.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)